Broadfin Capital’s Myriad Genetics MYGN Stock Holding History

Broadfin Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500,000	Closed	-$16.6M	–	44
2019 Q1	$16.6M	Buy	+500,000	New	+$15.2M	3.43%	10

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadfin Capital's MYGN Position: Q3 2019 in Review

Broadfin Capital sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 123,785 shares — an estimated $3.44M sold.

Broadfin Capital first reported a position in MYGN in Q1 2019 and held it in 2 quarters. The position peaked at $7.97M in Q1 2019. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Broadfin Capital reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Broadfin Capital sold 123,785 Myriad Genetics shares in Q3 2019, an estimated $3.44M.
Broadfin Capital first reported a position in Myriad Genetics in Q1 2019 and held it in 2 quarters.
Broadfin Capital's Myriad Genetics position peaked at $7.97M in Q1 2019.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.